


### Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1. (currently amended): A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



wherein X represents ~~OH, (C<sub>1-5</sub>) alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, or N(C<sub>1-5</sub>-alkyl)<sub>2</sub>~~ NH-C<sub>1-3</sub>-alkyl, or N(C<sub>1-3</sub>-alkyl)<sub>2</sub>;

R<sub>1</sub> is a residue derived from ~~one of the amino acid[[s]] Phe, Tyr, Trp, Pro, which each may be~~ optionally substituted with one or more methyl groups ~~(C<sub>1-5</sub>) alkoxy groups, (C<sub>1-5</sub>) alkyl groups or~~

one or more halogen atoms, as well as Ala, Val, Leu or ; or is a residue derived from the amino acid Ile;

R<sub>2</sub> is a residue derived from one of the amino acids Gly, Ala, or Ile, Val, Ser, Thr, Leu or Pro;

Y<sub>1</sub> and Y<sub>2</sub> independently from each other represent H or (C<sub>1-3</sub>) alkyl ~~(C<sub>1-5</sub>) alkyl~~;

~~R<sub>3</sub> and R<sub>4</sub> independently from each other represent H, OH, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>) alkoxy, provided that R<sub>3</sub> and R<sub>4</sub> are not both OH or (C<sub>1-5</sub>) alkoxy; and~~

~~R<sub>5</sub> represents H, OH, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>) alkoxy;~~  
or a pharmaceutically acceptable salt thereof.

2. (currently amended): The method according to claim 1, wherein X represents ~~(C<sub>1-5</sub>) alkoxy,~~  
~~NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, or N(C<sub>1-5</sub>-alkyl)<sub>2</sub>~~ NH-C<sub>1-3</sub>-alkyl, or N(C<sub>1-3</sub> alkyl)<sub>2</sub>.

3. (canceled)

4. (canceled)

5. (previously presented): The method according to claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

6. (previously presented): The method according to claim 1, wherein the neurodegenerative disease is mild cognitive impairment.


7. (currently amended): The method according to claim 1, wherein R<sub>1</sub> is a residue which is derived from one of the amino acids Phe, Tyr, Trp, ~~each of which may optionally be substituted with a one or more methyl groups~~ (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a or one or more halogen atoms ~~or which is derived from Ile.~~

8. (currently amended) The method according to claim 7, wherein  $R_1$  is a residue which is derived from Phe, which may optionally be substituted with a ~~(C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a~~ one or more halogen atoms.

9. (currently amended): The method according to claim 1, wherein  $R_2$  is a residue which is derived from the amino acid Gly-~~or Ile~~.

10. (previously presented): The method according to claim 1, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

11. (currently amended): A pharmaceutical composition comprising one or more compounds of the following formula (I):



(I)

wherein X represents ~~OH, (C<sub>1-5</sub>)-alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, or N(C<sub>1-5</sub>-alkyl)<sub>2</sub>NH-C<sub>1-3</sub>-alkyl, or~~  
N(C<sub>1-3</sub>-alkyl)<sub>2</sub>;

R<sub>1</sub> is a residue derived from ~~one of the amino acid~~[[s]] ~~Phe, Tyr, Trp, Pro~~, which each may be optionally substituted with one or more methyl groups ~~(C<sub>1-5</sub>)-alkoxy groups, (C<sub>1-5</sub>)-alkyl groups or one or more halogen atoms, as well as Ala, Val, Leu or ;~~ or is a residue derived from the amino acid Ile;

R<sub>2</sub> is a residue derived from one of the amino acids ~~Gly, Ala, or Ile, Val, Ser, Thr, Leu or Pro~~;

Y<sub>1</sub> and Y<sub>2</sub> independently from each other represent H or (C<sub>1-3</sub>)-alkyl ~~(C<sub>1-5</sub>)-alkyl~~;

~~R<sub>3</sub> and R<sub>4</sub> independently from each other represent H, OH, (C<sub>1-5</sub>)-alkyl or (C<sub>1-5</sub>)-alkoxy, provided that R<sub>3</sub> and R<sub>4</sub> are not both OH or (C<sub>1-5</sub>)-alkoxy; and~~

~~R<sub>5</sub> represents H, OH, (C<sub>1-5</sub>)-alkyl or (C<sub>1-5</sub>)-alkoxy;~~

and pharmaceutically acceptable excipients.

12. (currently amended): The pharmaceutical composition according to claim 11, wherein X represents ~~(C<sub>1-5</sub>)-alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, or N(C<sub>1-5</sub>-alkyl)<sub>2</sub>NH-C<sub>1-3</sub>-alkyl, or N(C<sub>1-3</sub>-alkyl)<sub>2</sub>.~~

13. (previously presented): The pharmaceutical composition according to claim 11 or 12, wherein R<sub>2</sub> is a residue which is derived from the amino acid Gly.

14. (previously presented): The pharmaceutical composition according to claim 11, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

15. (canceled)

16. (currently amended): The method according to claim 1, wherein  $R_1$  is a residue which is derived from Phe which is optionally substituted with one or more methyl groups ~~(C<sub>1-5</sub>) alkoxy groups, (C<sub>1-5</sub>) alkyl groups~~ or one or more halogen atoms, ~~or which is derived from the amino acid Ile,  $R_2$  is a residue derived from the amino acid Gly or Ile,  $R_3$ ,  $R_4$  and  $R_5$~~  represent a hydrogen atom, X is  $NH_2$ ,  $NH$  (C<sub>1-3</sub>) alkyl or  $N$ (C<sub>1-3</sub>-alkyl)<sub>2</sub>, and  $Y_1$  and  $Y_2$  independently from each other represent H or (C<sub>1-3</sub>) alkyl.

17. (currently amended): The pharmaceutical composition according to claim 11, wherein  $R_1$  is a residue which is derived from Phe which is optionally substituted with one or more methyl groups ~~(C<sub>1-5</sub>) alkoxy groups, (C<sub>1-5</sub>) alkyl groups~~ or one or more halogen atoms, ~~or which is derived from the amino acid Ile,  $R_2$  is a residue derived from the amino acid Gly or Ile,  $R_3$ ,  $R_4$  and  $R_5$~~  represent a hydrogen atom, X is  $NH_2$ ,  $NH$  (C<sub>1-3</sub>) alkyl or  $N$ (C<sub>1-3</sub>-alkyl)<sub>2</sub>, and  $Y_1$  and  $Y_2$  independently from each other represent H or (C<sub>1-3</sub>) alkyl.